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The brain is the primary organ that senses blood glucose levels and initiates a stress
response when blood glucose levels are too low (hypoglycemia). Insulin-dependent
people with Type 1 diabetes (T1DM) have an impaired ability to sense hypoglycemia and
an impaired ability to activate this counterregulatory response (CRR) to hypoglycemia.
As a result, T1DM are at a greater risk of experiencing insulin induced severe
hypoglycemic episodes, which can result in seizures, brain damage, or even death. Since
hypoglycemia is a major barrier that limits intensive blood glucose control, important
research initiatives are needed to prevent or reduce the burden of hypoglycemia for
people with Type 1 diabetes, specifically by defining the "mechanisms and modulators"
of brain glucose sensing. The experiments in this thesis were designed to investigate the
role and mechanism by which insulin may regulate brain glucose sensing.

Recent

evidence suggests that insulin acts in the brain to regulate glucose homeostasis, central

ii

nervous system (CNS) glucose sensing, and the CRR to hypoglycemia, but the site and
method of CNS insulin action are still unknown. This study 1) investigated whether
insulin acts on hypothalamic neurons to regulate brain glucose sensing and 2) ascertained
how insulin regulates glucose sensing by evaluating its effects on key glucose sensors
and CNS glucose uptake. Taking advantage of a genetic mouse model that chronically
lacks CNS insulin action (the neuronal insulin receptor knockout “NIRKO” mouse), this
report assessed whether CNS insulin signaling regulates the brain's ability to detect and
respond to hypoglycemia by analyzing glucose counterregulation and neuronal activation
in response to hypoglycemia. Further, to clarify a mechanism of CNS insulin action, this
study assessed whether insulin regulates key glucose sensors and/or CNS glucose uptake
by examining the expression patterns of key glucose sensing proteins, including glucose
transporters (GLUTs) and glucokinase (GK), and measuring regional brain glucose
utilization. Understanding how the brain regulates the counterregulatory response to
hypoglycemia is critical to devise therapies to combat severe hypoglycemia in diabetic
patients. Overall, this thesis provides new insights into insulin's role in the brain to
regulate CNS glucose sensing and the counterregulatory response to hypoglycemia.
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THESIS INTRODUCTION
Diabetes
Glucose homeostatic mechanisms exist to maintain stable blood glucose levels. When
mechanisms

controlling

whole-body

glucose

homeostasis

are

dysregulated,

pathophysiologic consequences, including diabetes, can occur (1;2).

Diabetes is a

classification of metabolic diseases characterized by chronically elevated blood glucose
levels (hyperglycemia). Diabetes develops predominately from impairments in the action
and/or production of the key regulatory hormone, insulin.

Insulin is an endocrine

hormone secreted by the pancreas that stimulates glucose uptake into peripheral tissues
and suppresses liver glucose production in order to reduce elevated blood glucose levels.
For patients with type 1 diabetes (T1DM), autoimmune destruction of the insulinproducing pancreatic β-cells results in insulin deficiency. In type 2 diabetic patients
(T2DM), insulin-responsive tissues (i.e. muscle and fat) become insensitive to the actions
of endogenous insulin, causing insulin resistance. Overt diabetes develops in type 2
diabetes when pancreatic β-cells fail to secrete enough insulin to compensate for the
degree of insulin resistance. For both type 1 and type 2 diabetic patients, the lack of
appropriate insulin release and/or signaling results in chronically elevated blood glucose
levels.

Due to hyperglycemia, patients with diabetes often suffer from a number of macro- and
microvascular complications, including retinopathy, hypertension, renal failure,
cardiovascular disease, etc., leading to increased morbidity/mortality and overall reducing
xii

quality of life (3-5). Diabetes is a major health problem in the United States, with nearly
25 million citizens (10% of the total population) affected with diabetes (6). Diabetes is a
chronic debilitating disease requiring years of treatment. As a result, diabetes causes an
undue burden on the United States healthcare system and costs nearly $200 billion
annually to treat cases of diabetes (6). This crisis is projected to worsen over the next 40
years as a recent Center for Disease Control and Prevention (CDC) study reported that
the number of Americans afflicted with diabetes may triple by 2050 (7).

To limit major complications associated with diabetes, diabetic patients are often
prescribed a drug regimen, along with lifestyle modifications, to help correct
hyperglycemia and to improve insulin sensitivity. Insulin secretagogues and sensitizers,
including sulfonylureas and thiazolidinediones, are commonly used oral medications that
stimulate endogenous insulin release or enhance insulin action on peripheral tissues. All
patients with type 1 and many patients with advanced type 2 diabetes require exogenous
insulin therapy to correct glucose levels.

An unfortunate consequence and major

complication of insulin therapy is the increased risk of dropping glucose levels too low,
causing hypoglycemia.

Hypoglycemia
As an obligate glucose consumer, the brain is critically dependent on glucose supply for
normal function.

Therefore, maintaining blood glucose levels within a tight

physiological range is essential to achieve whole-body glucose homeostasis. For patients
with diabetes, many of the glucose lowering drugs (including insulin) used to treat
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hyperglycemia can reduce blood glucose levels below the physiological range and induce
a state of hypoglycemia (low blood sugar). In response to hypoglycemia, the brain
coordinates a hierarchical stress (counterregulatory) response to rapidly restore normal
blood sugar levels (Figure 1). The normal counterregulatory response (CRR) initiates a
primary systemic hormone response, involving a reduction in endogenous insulin
secretion from the pancreatic β-cells and an increase in glucagon secretion from the
pancreatic α-cells. The counterregulatory stress response also involves activation of
critically important glucose sensing areas in the hypothalamus, which respond to
hypoglycemia by activating sympathetic efferent signals to the adrenal medulla to rapidly
release epinephrine (8-11).

The hypothalamic release of corticotrophin releasing

hormone (CRH) mediates release of adrenocorticotrophin hormone (ACTH) systemically
to trigger cortisol release from the adrenal cortex, which may be an important
counterregulatory response in the setting of more prolonged hypoglycemia. There is also
the development of autonomic symptoms which are mediated by the release of
catecholamines (norepinephrine and epinephrine).

These symptoms include tremor,

anxiety, and palpitations which occur as a result of norepinephrine and epinephrine being
released from sympathetic postganglionic neurons and/or the adrenal medulla and
sweating, hunger, and paresthesias which occur as a result of the release of acetylcholine
from sympathetic postganglionic neurons. The awareness of these autonomic symptoms
alert the hypoglycemic individual to take corrective action (i.e., consume sugar) to
correct the hypoglycemic episode. When blood glucose levels drop below 50mg/dL,
neuroglycopenic symptoms develop (impaired cognition, weakness, confusion, lethargy,
coma and death).

xiv

Many patients with diabetes experience frequent episodes of severe, temporarily
disabling hypoglycemia (12;13).

Severe hypoglycemia is associated with several

detrimental symptoms, including seizures, coma, brain damage, and even death (13).
Hypoglycemia is caused by relative insulin excess and the condition is made worse in the
setting of impaired counterregulation. There are many reasons why patients with both
Type 1 and long-standing Type 2 diabetes have defective counterregulatory responses to
hypoglycemia and are therefore susceptible to more frequent and more severe episodes of
hypoglycemia. Several components of the counterregulatory response (specifically the
suppression of endogenous insulin secretion and stimulation of glucagon and
catecholamine release) are blunted or completely absent in diabetic patients (14-17).
Accompanied by impaired counterregulation, intensive insulin therapy markedly
increases the risk of severe hypoglycemia in type 1 diabetic patients (3). As a result,
hypoglycemia stands as the rate-limiting step for tight glycemic management in diabetic
patients (18). This barrier of hypoglycemia prevents people with diabetes from achieving
the known benefits associated with intensive blood sugar control. To improve glycemic
management of diabetic patients, a better understand of hypoglycemic counterregulation
is needed. By understanding how the brain regulates the counterregulatory response to
hypoglycemia and identifying key glucose sensing systems in the central nervous system,
it will allow for the appropriate identification of clinical therapeutic strategies to combat
severe hypoglycemia in patients with diabetes.
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Insulin in the CNS
Once considered insulin-insensitive, insulin action in the brain has become an area of
intense investigation. Insulin and insulin receptors have been localized throughout the
central nervous system (CNS) (19-23) and act diversely to affect feeding, body weight,
reproduction, and neurotransmission (24-31). More importantly, CNS insulin action has
been implicated as a major contributor to the counterregulatory response to hypoglycemia
(32;33). Insulin has been shown to cross the blood-brain barrier to directly activate the
autonomic nervous system (34-38). Furthermore, in studies where insulin was selectively
directed to the brains of hypoglycemic dogs, the counterregulatory response was greatly
augmented (39;40). Conversely, genetic ablation of CNS insulin action (as seen in the
NIRKO model) resulted in impaired counterregulation (41). Also, insulin treatment has
been shown to increase the action potential frequency of glucose responsive neurons
during hypoglycemia (42). These studies suggest that insulin operates within the CNS to
regulate hypoglycemic counterregulation.

It is unclear how insulin modulates the counterregulatory response in the brain, but this
thesis approaches deciphering the mechanism by analyzing similarities between
mechanisms of insulin action in peripheral glucose sensors. Most interestingly, insulin
receptors demonstrate overlapping expression with key glucose sensing proteins in key
regions of the hypothalamus, specifically glucose transporters (GLUTs) and glucokinase
(GK). As a result, it is postulated that brain insulin action may mediate its effects on
glucose sensing via regulation of glucose transporters (GLUTs) and/or glucokinase (GK).

xvi

This thesis analyzes insulin’s influence over these proteins in order to gain a better
understanding of insulin’s role in CNS glucose sensing.

Central Nervous System (CNS) Glucose Sensing
In order to detect slight fluctuations in glucose levels, the body is equipped with
numerous glucose sensors located throughout the body, including the gut, portal vein,
pancreas, and brain (43-47).

Due to its high glucose demands, many studies have

confirmed that the brain serves as the primary glucose sensor and the hypothalamus
functions as the integrative center of glucose sensing (8-11). Within the hypothalamus,
glucose sensing predominates in discrete regions, namely the ventromedial hypothalamus
(VMH), arcuate nucleus (ARC), and paraventricular nucleus (PVN). Of which, the
region most studied is the VMH.

Several studies abolishing VMH function have

demonstrated its role in CNS glucose sensing. Specifically, creating lesions or chemical
destruction of the VMH deregulated peripheral glucose homeostasis (11;48-50).

While all neurons metabolize glucose as a fuel source, a set of critically important
neurons within the VMH and brain stem sense and respond to changes in blood sugar.
By coupling their neuronal activity (i.e., firing rate) in response to their metabolism of
glucose, these specialized neurons have been classified as “glucose sensing” neurons and
not merely as “glucose using” neurons. These glucose sensing neurons are categorized as
either glucose-excited neurons (GE), which increase their firing rate when extracellular
glucose concentrations are elevated or glucose-inhibited neurons (GI), which are
activated by decreases in extracellular glucose concentration or by cellular glucoprivation
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(50-52). Both neuronal populations are widely distributed throughout the brain, but
display distinct enrichment in hypothalamic and hindbrain regions classically associated
with neuroendocrine regulation, energy homeostasis, and nutrient metabolism.

The mechanism of CNS glucose sensing is not clearly defined but appears to be
dependent on the metabolism of glucose within key glucose sensing neurons (GSN).
Reports indicate that GSN located in the ventromedial hypothalamus (VMH) contain
critical glucose sensors that mediate many of the counterregulatory responses to
hypoglycemia (8-11). To better understand CNS glucosensing, researchers have drawn
clues from more widely studied glucose sensing mechanisms, including the classic
glucose sensing system—pancreatic β-cell (Figure 2). Glucose sensing in the β-cell is a
dose-dependent process that joins elevations in glucose uptake/metabolism to insulin
release.

Analogous to the β-cell, GE neurons enhance their firing activities when

extracellular glucose rises. Furthermore, the existences of key β-cell glucose sensing
proteins, including glucose transporters (GLUTs), glucokinase (GK), and ATP-sensitive
K+ channels (KATP), have been reported in hypothalamic nuclei (44;52-54). Therefore, it
is speculated that these proteins may have a broadened role to include CNS glucose
sensing. The mechanism of glucose sensing in GI neurons is even less characterized. GI
neurons contain many of the same glucose sensing proteins as GE neurons, including
glucose transporters and glucokinase (55). However, the mechanism linking increases in
glucose concentrations to suppression of neuronal firing may involve additional players,
including regulation of the sodium-potassium channel activity and/or ATP-sensitive
chloride channels, to facilitate glucose-mediated silencing (55-57).

In addition to
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regulating electrical activity, glucosensing neurons may also mediate their effects through
nutrient sensors or the release of neurotransmitters in the brain, including GABA
(inhibitory) and glutamate (excitatory) (58;59).

Glucose sensing neurons also play an important role in the detection of hypoglycemia
and the initiation of the counterregulatory response; therefore changing any key glucose
sensor may result in altered hypothalamic glucose sensing and impaired initiation of the
counterregulatory response.

As a consequence, these key glucose sensing proteins,

among other hypothalamic nutrient sensors, may serve as therapeutic targets to combat
hypoglycemia.

Facilitative Glucose Transporters (GLUTs)
Glucose transport is a fundamentally important process in energy metabolism. The body
needs to maintain a relatively constant supply of blood glucose to sustain brain
metabolism and to maintain transport of glucose to peripheral tissues for utilization and
storage (60). Facilitative glucose transporters (GLUTs) support the passive influx of
glucose into cells. Several GLUTs have been identified in the brain (61;62). Of these,
GLUT1 and GLUT3 are the predominate isoforms expressed in the brain (63). Although
found in lower quantities, GLUT2 is expressed in key glucose sensing regions (64;65).
Similar to its role in β-cell glucosensing, mounting evidence suggests that GLUT2 may
be involved in hypothalamic glucosensing (66;67).

GLUT4, the insulin-responsive

glucose transporter, is expressed along with the insulin receptor in many important brain
regions involved in glucose sensing (68;69).
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Glucokinase (GK)
Glucokinase (GK) is a hexokinase that regulates glucose phosphorylation and metabolism
in the β-cell and liver (44;55). Similar to its peripheral functions, GK may also play a
role in the hypothalamus to mediate glucose sensing (70). Demonstrated by both in-situ
hybridization and RT-PCR, glucokinase is expressed in several hypothalamic regions
(55;71). Further, modulating hypothalamic GK activity has been shown to regulate the
counterregulatory response to hypoglycemia. Specifically, studies were performed to
inhibit hypothalamic GK activity by injecting the glucokinase inhibitor alloxan or an
adenovirus expressing a GK short hairpin RNA (to chronically reduce GK hypothalamic
expression) into the ventricle that bathes the hypothalamus (intracerebroventricular—
ICV).

Results of these studies show that GK inhibition selectively enhanced the

epinephrine response to hypoglycemia (71). Conversely, enhancing GK activity with a
glucokinase activator (Compound A) markedly suppressed the counterregulatory
response (71).

Ion channels: ATP-sensitive K+ (KATP) and ATP-sensitive Cl- channels
ATP-sensitive K+ channels (KATP) may provide a link between glucose metabolism and
electrical activity in glucose sensing neurons. Several KATP channel subunits (Kir6.2,
SUR1, and SUR2) have been localized in key glucosensing regions of the hypothalamus
(72;73).

The involvement of the KATP channel in central glucose sensing and

counterregulation has been also shown by several in vivo studies. Either ICV or direct
VMH injection of the channel inhibitor glibenclamide blocks the counterregulatory
response to acute hypoglycemia or anti-metabolite-induced glucopenia (74).

KATP

xx

channel inactivation (via Kir6.2 gene knockout) also leads to an impaired
counterregulatory response to hypoglycemia.

Further, KATP inactivity correlates to

suppressed glucose-regulated firing activity of VMH neurons (75). In contrast, activation
of ATP-sensitive K+ channels in the VMH with channel opener diazoxide amplifies
counterregulatory hormone responses to hypoglycemia in normal and recurrently
hypoglycemic rats (76).

ATP-sensitive Cl- channels are postulated to play an important role in the electrical
activity of GI neurons. In response to decreased glucose levels, neuronal ATP levels are
reduced, the Cl− channel becomes inactivated, and the GI neuron becomes depolarized.
This form of ATP-activated Cl− conductance has been demonstrated in key glucose
sensing systems, namely the pancreatic islet cells (77). Further, an example of these Clchannels, cystic fibrosis transmembrane regulator (CFTR), CFTR mRNA and protein has
been localized in human and rat hypothalamus (78-80), suggesting a role of these
channels in central glucose sensing mechanisms.

Other Glucose Sensing Players: AMPK and Neurotransmitters
AMP-activated protein kinase (AMPK) is an important nutrient sensor present in the
brain. When nutrient supplies are low, there is an increase in cellular AMP, which leads
to allosteric activation of AMPK. AMPK activity stimulates catabolic pathways and
suppresses anabolic pathways to restore energy homeostasis.

In the hypothalamus,

AMPK activity is increased in response to insulin-induced hypoglycemia and reduced by
peripheral or ICV glucose infusion (81;82).

AMPK may also regulate the
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counterregulatory response to hypoglycemia. Enhancing VMH-AMPK activity with an
activator, AICAR, markedly increases endogenous glucose production during a
hypoglycemic clamp and improved the counterregulatory response in animals with
defective counterregulation (83;84). Conversely, blocking hypothalamic AMPK with
compound C, expressing a dominant negative form of AMPK, or reducing hypothalamic
AMPK expression via RNA interference strongly reduced counterregulation to insulininduced hypoglycemia (83).

Two major classes of neurotransmitters in the brain, GABA (inhibitory) and glutamate
(excitatory), have been postulated to play a role in CNS glucose sensing (58;59).
Blocking GABA receptors in the VMH stimulates counterregulatory response to
hypoglycemia (59;85) while blocking glutamate release in the VMH impairs the
counterregulatory response to hypoglycemia (58).

These studies suggest that

neurotransmission in VMH neurons provide an unappreciated role to the CNS glucose
sensing mechanism. Further, modulation of neurotransmission in the brain may act as an
additional clinical target to prevent hypoglycemia.

xxii

Brain

Pancreas

Hypothalamus
PVN

β−cell

VMH

α−cell

ARC

Anterior pituitary

H-P-A
Axis

Adrenal cortex

Sympathetic nervous system

Insulin

Glucagon

Adrenal medulla

Norepinephrine
Cortisol

Epinephrine

Acetylcholine

Figure 1. Glucose sensing and the physiological response to hypoglycemia.
In the normal response to hypoglycemia, the brain (esp. the hypothalamus) coordinates
and triggers a stress response to restore euglycemia. This process includes stimulating the
HPA axis and sympathetic nervous system to increase production of key
counterregulatory hormones. Cortisol (via ACTH release) and epinephrine secretions
arise from the adrenal cortex and medulla, respectively. The sympathetic nervous system
also increases norepinephrine and acetylcholine release, to stimulate observable
symptoms of hypoglycemia. At the level of the pancreas, endogenous insulin secretion
from the β-cell is suppressed while glucagon release from the α-cell is elevated. This
processes work in unison to normalize blood glucose levels.
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Figure 2. Proposed mechanism of glucose sensing in glucose sensing neurons.
During euglycemia or hyperglycemia, the proposed glucose-excited (GE) glucose sensing
mechanism requires glucose uptake via glucose transporters (GLUTs), glucose
phosphorylation by the rate-limiting enzyme glucokinase (GK), and subsequent
metabolism of glucose to increase the intracellular ATP-to-ADP ratio. Following glucose
metabolism, closure of ATP-sensitive K+ channels, membrane depolarization, and
neuronal firing occurs. When glucose levels fall, as seen during hypoglycemia, neuronal
activity is decreased in GE neurons and glucose-inhibited (GI) neurons are activated.
Similar to GE neurons, glucose sensing in GI is proposed to involve GLUTs, GK, and
altered ATP-to-ADP ratio. Glucose sensing in the GI is speculated to also involve ATPsensitive Cl- channels and activation of the fuel sensor, AMPK, leading to initiation of the
counterregulatory response to hypoglycemia.

∆Vm: change in membrane potential,

membrane depolarization.
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CHAPTER 1. HYPOGLYCEMIC COUNTERREGULATION AND NEURONAL
ACTIVATION IN A MODEL OF CHRONIC CENTRAL NERVOUS SYSTEM
(CNS) INSULIN RESISTANCE

1

ABSTRACT
An impaired ability to sense and appropriately respond to insulin-induced hypoglycemia
is a common and serious complication faced by insulin-treated diabetic patients. This
study tests the hypothesis that insulin acts directly in the brain to regulate critical glucose
sensing neurons in the hypothalamus to mediate the counterregulatory response to
hypoglycemia. To delineate insulin actions in the brain, neuron-specific insulin receptor
knockout (NIRKO) mice and littermate controls were subjected to graded hypoglycemic
(100, 70, 50, and 30 mg/dL) hyperinsulinemic (20 mU.kg-1.min-1) clamps. Subsequently,
counterregulatory responses and hypothalamic neuronal activation (with transcriptional
marker c-fos) were measured. Additionally, electrophysiological activity of individual
glucose-inhibited (GI) neurons was measured.

NIRKO mice revealed a glycemia-

dependent impairment in the sympathoadrenal response to hypoglycemia and
demonstrated markedly reduced (70%) hypothalamic c-fos activation in response to
hypoglycemia. Further, GI neurons in the ventromedial hypothalamus of NIRKO mice
displayed significantly blunted glucose responsiveness to decreases in extracellular
glucose from 2.5 to 0.5mM (membrane potential and input resistance responses were
blunted 66% and 80%, respectively). We conclude that insulin acts in the brain to
regulate the counterregulatory response to hypoglycemia by directly altering glucosemediated activation of hypothalamic neurons and shifting the glycemic levels necessary
to elicit a normal sympathoadrenal response to hypoglycemia.

2

INTRODUCTION
Intensive insulin therapy markedly increases the risk of severe hypoglycemia in people
with type 1 (86) and type 2 (4) diabetes. Thus, hypoglycemia is the rate-limiting step for
tight glycemic management in diabetic patients. In response to hypoglycemia, glucose
sensors in the central and peripheral nervous system coordinate efferent autonomic
responses resulting in the release of key counterregulatory hormones—glucagon,
norepinephrine, epinephrine, and cortisol. This coordinated response stimulates hepatic
glucose output and restricts glucose utilization in order to increase blood sugar levels.
Patients with diabetes often have an impaired ability to sense and respond to
hypoglycemia (12;13;87) because several components of the counterregulatory response
have been shown to be either absent (i.e. fall in insulin, rise in glucagon) or markedly
blunted (i.e. the sympathoadrenal response) (16;17).

While hypoglycemia is caused by absolute or relative insulin excess, the role of insulin in
regulating the counterregulatory response is unclear. Studies have demonstrated that
increased insulin levels may augment (32;88-90), diminish (91), or not change (33;92-94)
the sympathoadrenal response to hypoglycemia. Given recent evidence indicating that
insulin acts in the brain (28), some studies have investigated whether insulin’s putative
actions in regulating the counterregulatory response might be mediated via actions in the
central nervous system. Again, conflicting reports suggest that insulin may act centrally
to enhance (39-41), reduce (95;96) or not alter (97) the sympathoadrenal response to
hypoglycemia. In this study, the neuronal specific insulin-receptor knockout (NIRKO)
mouse model, which chronically lacks central nervous system (CNS) insulin signaling
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(28;98), was used to investigate the role by which brain insulin action regulates central
glucose sensing and the counterregulatory response to hypoglycemia.

4

MATERIALS AND METHODS
Animals. Mice homozygous for the floxed insulin receptor allele (IRlox-lox) were bred
with transgenic mice that express Cre recombinase cDNA from the rat nestin promoter to
generate (IRlox-lox:nestin-Cre+/-) nervous system specific insulin receptor knockout
(NIRKO) mice (28). Genotypes were determined by PCR of tail DNA. Unless otherwise
indicated, 2-4 month old NIRKO (IRlox-lox:nestin-Cre+/-) and littermate control (Control,
IRlox-lox:nestin-Cre-/-) mice were used for these experiments. All mice were housed on a
12-hour light/dark cycle and fed a standard rodent chow (Mouse Diet 9F, PMI Nutrition
International, St. Louis, MO) ad libitum. All procedures were in accordance with the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
and were approved by the Animal Studies Committee of Washington University.

Hypoglycemic-hyperinsulinemic

glucose

clamps.

Mice

anesthetized

with

ketamine/xylazine (87 and 13.4 mg/kg IP) were implanted with catheters (MRE 025,
Braintree Scientific Inc., Braintree, MA) into both the right internal jugular and the left
carotid or femoral artery. After a 5-7 day recovery period, hyperinsulinemic (20mU.kg1

.min-1) hypoglycemic clamps were performed in 5-hour fasted, awake, unrestrained,

NIRKO and control mice (n=6-9 per group). To create various degrees of hypoglycemic
stress, arterial blood glucose (~2µL) was measured at ten-minute intervals as a
continuous infusion (20 mU/kg/min) of human regular insulin (Humulin, Eli Lilly and
Co.) in 0.1% BSA and 50% dextrose were administered. The rate of intravenous 50%
dextrose infusion was variable and carefully adjusted to create equivalent levels of mild
(70mg/dL), moderate (50mg/dL), and severe hypoglycemia (30mg/dL) as well as a
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euglycemic (110mg/dL) control.

HPLC-purified [3-3H]-glucose tracer (NEN Life

Science Products Inc., Boston, MA) was infused (10µCi bolus followed by 0.1µCi/min
continuous infusion) for the assessment of hepatic glucose production (99). After a 90
minute basal period, three blood samples (10µL) at 10 minute intervals were taken for
hepatic glucose production determination. Three blood samples were also taken during
the last half hour of the clamp. An additional blood sample (130µL) was obtained for
hormonal

measurements

(insulin,

glucagon,

epinephrine,

norepinephrine,

and

corticosterone) during the basal period and at the end of the clamp. Whole-body glucose
turnover was determined during the steady state from the ratio of the [3H] glucose
infusion rate to the measured specific activity of plasma glucose (99). Hepatic glucose
production (HGP) was determined by subtraction of the glucose infusion rate from the
whole-body glucose turnover (99).

Hypoglycemia-induced c-fos expression.

Awake, 5-hour fasted NIRKO (n=4) and

littermate controls (n=6) were given a single intraperitoneal (IP) injection of high dose
insulin (3.0-3.5U/kg) to achieve a consistent and stable hypoglycemic insult (~30mg/dL)
for 2 hours. Euglycemic controls (~110mg/dL, n=4 per group) were given an IP injection
of saline. After a 2 hour duration of hypoglycemia (or euglycemia), mice anesthetized
with isofluorane and transcardially perfused with 0.01 M PBS (Sigma, Saint Louis, MO)
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA). The
brains were immersed in 4% paraformaldehyde overnight and then cryoprotected in 30%
sucrose. Brain sections were then processed for c-fos immunostaining. Free-floating
brain sections (20-30µm) containing the paraventricular nucleus (PVN) of the
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hypothalamus were blocked with 30% normal goat serum diluted in 0.1% Triton100/PBS and then incubated overnight at 4°C with c-fos antibody (1:2000, Ab-5,
Calbiochem, San Diego, CA). Subsequently, the sections were mounted on slides and
processed with biotinylated goat anti-rabbit immunoglobulin G (1:200) using the Elite
ABC kit (Vector Laboratories, Burlingame, CA). As a negative control, alternative
sections were incubated without primary antibodies. Anatomical landmarks were used to
identify the paraventricular nucleus of the hypothalamus (100). Positively stained cells
were counted by a blinded investigator. Four to six anatomically matched sections per
mouse were quantified for statistical purposes.

Electrophysiological studies. Male 14-28 day old NIRKO and littermate control mice
were anesthetized and transcardially perfused with ice-cold oxygenated perfusion. On
the day of the experiment, mice were anesthetized and transcardially perfused with icecold oxygenated (95% O2/5% CO2) perfusion. Sections (350µm) through the
hypothalamus were made on a vibratome (Vibroslice; Camden Instruments). The brain
slices were maintained at 34°C in oxygenated high-Mg2+ low-Ca2+ artificial cerebrospinal
fluid for 30 minutes and then transferred to normal oxygenated ACSF (2.4 mmol/l CaCl2
and 1.3 mmol/l MgCl2) for the remainder of the day. Viable neurons were visualized and
studied under infrared differential-interference contrast microscopy using a Leica DMLS
microscope equipped with a 40× long working-distance water-immersion objective.
Current-clamp recordings (standard whole-cell recording configuration) from neurons in
the VMH were made using an Axopatch 1D amplifier (Axon Instruments, Foster City,
CA) as previously described (101;102). During recording, brain slices were perfused at
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10mL/min with normal oxygenated ACSF.

Borosilicate pipettes (1–3 MΩ; Sutter

Instruments, Novato, CA) were filled with an intracellular solution containing (in
mmol/l): 128 K-gluconate, 10 KCl, 4 KOH, 10 HEPES, 4 MgCl2, 0.5 CaCl2, 5 EGTA,
and 2 Na2ATP; pH 7.2. Osmolarity was adjusted to 290–300 mOsm with sucrose. Input
resistance was calculated from the change in membrane potential in response to small
500-msec hyperpolarizing pulses (−10 to −20pA) given every 3 seconds.

Briefly,

hyperpolarizing current pulses varying from −10 to −120 pA were applied at 10- or 20pA increments. At each increment, four pulses were applied. The duration of each pulse
was 500 ms, and pulses were applied every 3 seconds. The membrane potential response
during the last 5 ms of each pulse (when dV/dt = 0) was measured, and the average of the
four pulses at each amplitude was calculated. The membrane potential response was
measured only after the membrane response to altered extracellular glucose had
stabilized, and this value was compared with controls that were measured immediately
before changing extracellular glucose. Individual glucose inhibited (GI) neurons were
identified as those neurons that increased their action potential frequency, membrane
potential, and input resistance with decreases in extracellular glucose from 2.5 to 0.1mM.

Plasma Assays. Blood glucose was measured by a glucometer (Becton, Dickinson and
Company, Franklin Lakes, NJ) while plasma glucose was assayed by the glucose oxidase
method and a spectrophotometer (BioTek Instruments, Inc., Winooski, VT).
Radioimmunoassays were performed for glucagon (LINCO Research, Inc., St. Charles,
MO) and corticosterone (ICN Biomedicals, Inc., Costa Mesa, CA). Insulin was assayed
by enzyme-linked immunosorbent assay (ELISA) (Chrystal Chem. Inc., Downers Grove
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IL). Plasma epinephrine and norepinephrine were measured with a single isotope
derivative (radioenzymatic) method (103).

Statistics. All values are presented as the mean ± standard error of the mean (SEM).
Statistical significance was set at p<0.05, as determined by Student’s t test.
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RESULTS
Brain Insulin Action is Necessary for Full Sympathoadrenal Response to Hypoglycemia
To characterize the counterregulatory response to hypoglycemia in NIRKO mice, a series
of hyperinsulinemic glucose clamps were performed. Blood glucose was clamped at 110,
70, 50 and 30mg/dL in control and NIRKO mice to induce various degrees of
hypoglycemia (mild=70mg/dL, moderate=50mg/dL, and severe hypoglycemia=30mg/dL)
or no hypoglycemia (euglycemic clamp=110mg/dL) (Figure 3). In response to insulin
infusion, plasma insulin levels were similarly elevated in NIRKO and control mice
(Figure 4). Severe hypoglycemia (30mg/dL) resulted in a 6-fold increase in glucagon
levels and ~60% increase in corticosterone levels, but these increases were similar in both
groups (Figures 4 and 5). Norepinephrine levels trended lower in NIRKO mice during
moderate (50mg/dL) and severe (30mg/dL) hypoglycemia, but the difference did not
reach significance (Figure 5).

In response to high dose insulin (20mU.kg-1.min-1), hepatic glucose production was
completely inhibited during the hyperinsulinemic clamp at glycemic levels of 100, 70,
and 50mg/dL. During severe hypoglycemia (30mg/dL), hepatic glucose production rose
significantly; however, the rise in hepatic glucose production was significantly blunted in
NIRKO mice (Figure 6). The epinephrine response was significantly impaired in NIRKO
mice during moderate (50mg/dL) and severe (30mg/dL) hypoglycemia (Figure 7). The
epinephrine response was highly correlated to glycemia levels in both control (R2=0.76)
and NIRKO (R2=0.75) mice.

Based on the shift in the hypoglycemia-epinephrine

response curve (Figure 7-inset), the data was fitted to a four parameter logistic curve and
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EC50 values were determine for control (46.5±3.6 mg/dL) and NIRKO (34.5±11.7mg/dL)
mice.

Absent CNS Insulin Action Impairs Hypothalamic Neuronal Activation to Hypoglycemia
In order to assess the brain’s response to hypoglycemia, c-fos-based functional mapping
was used to demonstrate activated neurons and functional circuits that respond to
hypoglycemic stress (104).

Euglycemic (~110mg/dL) controls displayed low c-fos

expression in the hypothalamus.

In response to insulin-induced hypoglycemia

(31.5±3.1mg/dL), both NIRKO and control mice markedly increased c-fos expression
within the paraventricular nucleus (PVN) of the hypothalamus.

However, NIRKO

animals showed a 3-fold impairment in c-fos activation as compared to controls (Control:
99±16 vs. NIRKO: 31±5, p<0.01) (Figure 8).

Intact Neuronal Activation and Physiological Response to Extreme Glucose Deprivation
To determine whether NIRKO mice displayed an absolute impairment in their ability to
respond to hypoglycemic insults, NIRKO mice were subjected to extreme glucose
deprivation (blood glucose level below 30mg/dL) to evaluate their ability to fully
stimulate a sympathoadrenal response and/or activate neurons in the PVN. Similar to the
severe hypoglycemic insult, both NIRKO and control mice significantly stimulated
neuronal activity as well as catecholamine responses to extreme glucose deprivation.
However, when glucose levels were kept below 30mg/dL, NIRKO mice elevated c-fos
expression and catecholamine levels similar to those seen in control mice (Figure 9).
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Impaired Glucose Sensing in Individual Glucose-Inhibited Neurons
Whole-cell current clamp recordings were performed to evaluate the glucose sensitivity
of individual glucose-inhibited (GI) neurons in the ventromedial hypothalamus (VMH)
(Figure 10). As expected for VMH GI neurons bathed in sufficient 2.5mM glucose,
action potentials in this basal state were absent in recordings from both control and
NIRKO mice. There were also no group differences in membrane potential (MP) or
input resistance (IR) in 2.5mM glucose (Control: MP -57±4 mV, IR 1209±272 MΩ;
NIRKO: MP -59±3 mV, IR 1016±162 MΩ).

Further, no group differences were

observed in GI neurons in response to a maximal glucose decrease from 2.5 to 0.1mM.
In contrast, GI neurons in NIRKO mice had a significantly impaired change in membrane
potential and input resistance (66% and 80% impairment, respectively) in response to a
glucose decrease from 2.5 to 0.5mM (Figure 11).
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Figure 3.

Glucose
lucose profile from h
hyperinsulinemic,
emic, graded hypoglycemic clamp

protocol. Blood glucose levels are shown for NIRKO (closed
ed circles) and control (open
circles) mice (n=6-88 mice per group).

After basal sampling, insulin was infused

(20mU.kg-1.min-1) and blood glucose levels were measured at ten
ten-minute
minute intervals via
arterial sampling. By adjusting th
thee rate of intravenous glucose infusion, glucose levels
were carefully lowered, then clamped at matched, pre
pre-determined
determined glycemic levels (110,
70, 50, and 30mg/dL) to create various degrees of hypoglycemic stress (none, mild,
moderate, and severe, respective
respectively).
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Figure 4.

Pancreatic hormone levels during graded hyperinsulinemic glucose

clamps. Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8
mice per group). Top: By experimental design, insulin levels rose markedly, and
similarly between groups during the hyperinsulinemic clamps. Bottom: Glucagon levels
in both treatment groups rose significantly above basal levels (p<0.05) during moderate
and severe hypoglycemia but similarly between treatment groups.
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Figure 5. Corticosterone and norepinephrine levels during graded hyperinsulinemic
glucose clamps. Results are shown for NIRKO (closed bars) and control (open bars)
mice (n=6-8 mice per group). Top: Corticosterone levels in both treatment groups rose
significantly above basal levels (p<0.05) during moderate and severe hypoglycemia but
similarly between treatment groups. Bottom: Norepinephrine levels in both treatment
groups rose significantly higher from the basal period during moderate and severe
hypoglycemia but there was no difference between NIRKO and control responses.
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Figure 6.

Hepatic glucose production during graded hyperinsulinemic glucose

clamps. Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8
mice per group).

Hepatic glucose production (HGP) before and during the

hyperinsulinemic clamps was determined by tracer dilution methodology.

Hepatic

glucose production (HGP), in the basal period prior to insulin infusion, was the same in
control and NIRKO mice. During the hyperinsulinemic glucose clamps at mild and
moderate hypoglycemia, HGP was suppressed. In spite of the hyperinsulinemia, during
severe hypoglycemia (30mg/dL), HGP rose significantly, but remained lower in NIRKO
as compared to control mice. (*p<0.05)
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Figure 7. Adrenomedullary response in a series of hyperinsulinemic glucose clamps.
Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8 mice per
group). The epinephrine response was significantly impaired in NIRKO mice during
moderate (50mg/dL) and severe (30mg/dL) hypoglycemia.

The inset picture

demonstrates a shift in the hypoglycemia dose-response curve by the solid (controls)
versus dashed (NIRKO) line. (*p<0.05 vs. control)
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Figure 8. Blunted neuronal activation in response to hypoglycemia seen in NIRKO
hypothalamus.

Top:

Representative images of matched hypothalamic sections

highlighting c-fos staining in the paraventricular nucleus (PVN) in NIRKO (right image)
and littermate controls (left image) after a 2 hour hypoglycemic insult.

Bottom:

Quantification of c-fos positive cells stimulated during euglycemia (n=4 mice per group)
and matched hypoglycemia in NIRKO (n=4, closed bars) and littermate control (n=6,
open bars) mice (left). Blood glucose levels are shown for NIRKO (closed circles) and
control (open circles) mice during the hypoglycemic insult, illustrating a well-matched,
stable hypoglycemic insult (right). (**p<0.01 vs. control)
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Figure 9. Intact neuronal activation and catecholamine response to extreme glucose
deprivation. Results shown for NIRKO (closed bars) and littermate control (open bars)
mice (n=3-6 per group). Top: Quantification of c-fos positive cells from a 2 hour
hypoglycemic insult maintained below 30mg/dL glucose in NIRKO mice and littermate
controls.

Bottom:

Catecholamines are robustly induced during extreme glucose

deprivation. By maintaining blood glucose levels below 30mg/dL, NIRKO mice are able
to stimulate both epinephrine (left) and norepinephrine (right) levels equally to control
mice.
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Figure 10.

0.5 mM G

Individual glucose-inhibited neurons demonstrate impaired glucose

responsiveness in NIRKO mice. Representative traces from standard whole-cell current
clamp recordings of VMH glucose-inhibited (GI) neurons from a C57 control and
NIRKO mouse in response to decreases in extracellular glucose (G) from 2.5 mM to 0.1
and 0.5mM. Top: In a control mouse, decreased G from 2.5 to 0.1 mM and 2.5 to 0.5
mM resulted in membrane depolarization, increased input resistance and the appearance
of action potentials in this GI neuron. Bottom: In a GI neuron from a NIRKO mouse,
decreased G from 2.5 to 0.1 mM resulted in membrane depolarization, increased input
resistance and the appearance of action potentials identifying it as a GI neuron; however,
this effect was not observed when G decreased from 2.5 to 0.5 mM. The resting
membrane potential in 2.5 mM G is represented by the dashed line and is noted to the
right of each trace. The upward deflections indicate action potentials and the downward
deflections represent the membrane response to a constant current hyperpolarizing pulse.
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Figure 11. Changes in membrane potential and input resistance reduced in NIRKO
glucose-inhibited neurons.

Top:

Graphs quantifying the percentage change of

membrane potential (left) and input resistance (right) when identifying GI neurons in
NIRKO (n=7, closed bars) and control (n=6, open bars) mice (decreases in extracellular
glucose (G) from 2.5 to 0.1mM G). As noted, there is no difference between groups.
Bottom: In response to lowering G from 2.5 to 0.5mM G, the percentage change in
membrane potential (left) and input resistance (right) of glucose-inhibited neurons was
significantly lower in NIRKO compared to littermate controls. (*p<0.05, **p<0.01)
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DISCUSSION
Insulin’s role in regulating the counterregulatory response to hypoglycemia is an area of
active investigation. Insulin has been shown to increase (32;39-41;88-90), diminish
(91;95), and not alter (33;92-94;97) the sympathoadrenal response to hypoglycemia. In
this study, using a model of chronic brain insulin receptor deficiency, it was
demonstrated that insulin action in the brain, 1) regulates the glucose sensitivity of
glucose sensing neurons in the VMH, 2) regulates hypoglycemia-induced neuronal
activation, and 3) modulates the sympathoadrenal response to hypoglycemia by altering
the glycemic level required to elicit appropriate sympathoadrenal responses.

In these studies, a ~60% rise in corticosterone was observed in response to severe
hypoglycemia in NIRKO and control mice (Figure 5). Although not well characterized in
mice, this degree of hypothalamic-pituitary-adrenal (HPA) induced increment in
corticosterone is consistent with other groups (105-109). Contrary to the stimulatory
effect of insulin on the cortisol response to hypoglycemia observed in canine models
(39;40), these studies in mice demonstrate that the absence of brain insulin action does
not impair the HPA axis response to hypoglycemia.

Reports of insulin actions in the CNS in modulating the glucagon response to
hypoglycemia are variable, with studies demonstrating insulin to increase (39;40),
decrease (95), or not effect (41;97) the glucagon response to hypoglycemia. In the
current studies, the pancreatic α-cell response to severe hypoglycemia showed a 6-fold
increase in plasma glucagon levels that was not altered by the absence of CNS insulin
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receptors in NIRKO mice. Interestingly, although catecholamines stimulate the α-cell,
the impaired catecholamine response to hypoglycemia did not diminish the full glucagon
response in NIRKO mice (Figure 4). These results indicate that factors other than central
insulin action and systemic catecholamine responses (perhaps, local glycemia, intra-islet
insulin/zinc, direct innervations, etc.) are more important mediators of the glucagon
response to hypoglycemia.

The absence of brain insulin receptors resulted in a significantly impaired epinephrine
response in NIRKO mice during moderate (50mg/dL) and severe (30mg/dL)
hypoglycemia. However, the absence of brain insulin signaling did not result in total
deficiency of hypoglycemic counterregulation.

An epinephrine response of ~1500

pg/mL, which was achieved during moderate hypoglycemia (50mg/dL) in controls, was
also elicited at a lower blood glucose level (30mg/dL) in NIRKO mice (Figure 7).
Further, NIRKO mice were able to stimulate a comparable catecholamine response to
controls when blood glucose levels were lowered well below 30mg/dL (Figure 9).
Consistent with these findings, the shift in the hypoglycemia-epinephrine response curve
(Figure 7-inset) indicates that in the absence of insulin signaling, NIRKO mice needed to
reach lower glycemic levels to appropriately activate their adrenomedullary response.
While insulin infusion suppressed hepatic glucose production during the clamps, only
during severe hypoglycemia (30mg/dL) was the counterregulatory response of a
sufficient magnitude to overcome the suppressive effects of insulin and significantly
increase hepatic glucose production. In NIRKO mice, however, the counterregulatoryinduced stimulation of hepatic glucose production was significantly blunted during severe
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hypoglycemia (Figure 6), consistent with an impaired sympathoadrenal response. These
findings indicate that chronic lack of CNS insulin action alters glucose sensing and/or
responsiveness, leading to an impaired sympathoadrenal response and an impaired ability
to defend against iatrogenic hypoglycemia.

Increased c-fos expression in the paraventricular nucleus (PVN) has been used as a
marker of transcriptional activity in stress-related neural circuitry (104;110-112).
Expression of c-fos was therefore measured to determine whether the impaired
sympathoadrenal response in the NIRKO mice was related to impaired activation of
hypothalamic sensing neurons (Figures 8 and 9). During hypoglycemia, increased c-fos
expression was predominantly observed in the PVN and not seen in the VMH, consistent
with other studies (113;114). Hypoglycemia-induced c-fos activation in the PVN may
represent direct activation in response to hypoglycemia or indirect activation in response
to afferent input from other areas containing glucose sensing neurons. Thus, the impaired
c-fos activation in the PVN of NIRKO mice in response to severe hypoglycemia could
represent reduced glucose sensing of PVN neurons; or given the abundance of insulin
receptors in important VMH glucose sensing neurons, an indirect reduction in afferent
inputs from glucose sensing neurons in the VMH. Whether this defect indicates impaired
direct or indirect glucose sensing, the reduced c-fos activation in NIRKO mice was
profound and consistent with other models of impaired glucose sensing and impaired
counterregulation (112;115).
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Whole cell current clamp recordings of spontaneous electrical activity were made in
individual glucose-inhibited (GI) neurons to assess responses of individual glucose
sensing neurons in the VMH.

While a direct relationship between glucose sensing

neurons and sympathoadrenal activation has yet to be definitively established, it is
noteworthy that the ability of VMH GI neurons to sense a fall in ambient glucose levels is
impaired under several conditions where the sympathoadrenal response to hypoglycemia
is also impaired (i.e. rats treated with recurrent hypoglycemia or streptozotocin-induced
diabetes) (102;116;117). In NIRKO mice, the observed impaired response of VMH GI
neurons to reductions in glucose levels (Figures 10 and 11) is entirely consistent with the
impaired neuronal (c-fos) activation (Figure 8) and the impaired sympathoadrenal
activation during severe hypoglycemia (Figure 7). Further, the sympathoadrenal and cfos findings along with the electrophysiological findings that NIRKO GI neurons respond
normally to maximal glucose deprivation (blood glucose less than 30mg/dL and 0.1mM
G), but show impaired responses at 0.5mM are consistent with a relative, not absolute,
impairment in glucose sensing (Figures 9-11). These results indicate that insulin acts
directly in the brain to regulate the glucose sensing ability of hypothalamic GI neurons
that are critically important and functionally linked in mediating the sympathoadrenal
response to hypoglycemia.

Of particular interest is that GI neurons of NIRKO mice have an impaired ability to
respond to a fall in glucose even in the absence of insulin administration. Combining
these in vitro findings to the in vivo findings suggest that it may not solely be a failure of
insulin to acutely activate its receptor that leads to impaired glucose sensing and altered
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neuronal responses; but rather, we propose that the chronic lack of insulin signaling in
NIRKO mice causes long-term adaptations in gene transcription/transduction (i.e. altered
expression of key hypothalamic glucose sensing proteins), leading to impaired glucose
sensing. Alternatively, since neuronal nitric oxide (NO) production is required for GI
neurons to sense decreased glucose (118;119) and insulin enhances NO production in
VMH GI neurons (118), the chronic lack of insulin signaling in NIRKO mice may led to
impaired glucose sensing by impairing nitric oxide production. It is entirely plausible
that the chronic actions of insulin may be mechanistically very different from the acute
actions of insulin in regulating neuronal glucose sensing and the counterregulatory
response to hypoglycemia.

In summary, it is shown that the chronic lack of insulin receptor signaling in the central
nervous system, 1) attenuates individual hypothalamic GI neuronal responses to low
glucose, 2) impairs hypothalamic neuronal activation in response to hypoglycemia, and
3) reduces the sympathoadrenal response to hypoglycemia by shifting the glycemic level
necessary to elicit appropriate sympathoadrenal responses. It is concluded that insulin
acts directly in the brain to regulate both glucose sensing in hypothalamic neurons and
the counterregulatory response to hypoglycemia. Since insulin-treated diabetic patients
have an impaired ability to sense and appropriately respond to insulin-induced
hypoglycemia, the mechanisms by which insulin regulates central nervous system
glucose sensing need to be actively investigated as research scientists endeavor to
supplant insulin-induced hypoglycemia as the rate-limiting factor in the glycemic
management of diabetes.
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CHAPTER 2. INSULIN-REGULATED GLUCOSE TRANSPORTER GLUT4
MAY MEDIATE THE UNIQUE RESPONSE TO HYPOGLYCEMIA SEEN IN
MICE LACKING BRAIN INSULIN ACTION
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ABSTRACT
Insulin acts in the brain to affect numerous physiological functions, including
reproduction, neurotransmission, appetite, and glucose homeostasis. Recent reports in
the CNS insulin receptor knockout (NIRKO) mouse also indicate a significant role of
insulin action in the brain to regulate hypoglycemic counterregulation and glucose
sensing. However, it is unclear whether these impaired responses in NIRKO mice are
unique to hypoglycemia. Further, the mechanism of insulin action in the brain must still
be clarified. In this study, experiments were conducted to determine whether the NIRKO
model system exhibits a generalized (not hypoglycemia-specific) defect in the autonomic
nervous system (ANS) mediated stress response.

It was found that NIRKO mice

displayed normal physiological responses to various generalized stressors (i.e. restraint,
heat, and cellular glucopenia) comparable to littermate controls.

To decipher a

mechanism of CNS insulin action and glucose sensing, key glucose sensing proteins,
including glucose transporters (GLUTs) and glucokinase (GK), were analyzed and
measured. These glucose sensors were highly enriched in the ventromedial hypothalamus
(VMH) and arcuate nucleus (ARC) of both NIRKO and control mice. GLUT1 and
GLUT3 protein and glucokinase mRNA and protein expression levels were not
significantly altered in NIRKO mice. Interestingly, expression of the insulin-responsive
glucose transporter, GLUT4, within the ARC and VMH of NIRKO mice was found to be
only 68% of control mice (p<0.05). In summary, lack of insulin signaling in the brain led
to a hypoglycemia-specific impairment in the sympathoadrenal response to hypoglycemia
noted in this model. Further, absent brain insulin action resulted in marked changes in
glucose transporter expression, specifically GLUT4, which may account for the

28

previously noted glucose sensing impairment unique to this mouse model. Therefore, we
conclude that insulin acts in the brain to regulate GLUT4 expression in critically
important sites within the hypothalamus necessary for normal brain glucose sensing and
the normal sympathoadrenal response to hypoglycemia.
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INTRODUCTION
Insulin signaling is involved in many cellular processes, causing diverse effects on
metabolism, longevity, and stress responses in various model systems (120). Insulin’s
actions also extend to the central nervous system where insulin can directly regulate food
intake, body weight, and glucose homeostasis (24-31). As seen in the NIRKO model,
chronic lack of brain insulin signaling results in an impaired sympathoadrenal response to
hypoglycemia (41). Due to insulin’s ability to diversely effect disparate processes as well
as cross the blood-brain barrier to directly activate the autonomic nervous system (3438), it is unclear whether the hypoglycemia impairment found in NIRKO mice is specific
to altered glucose sensing or due to a generalized defect in its ability to respond to
stressful insults.

Insulin’s specific role in regulating CNS glucose sensing is ill-defined but growing
evidence supports the hypothalamus (specifically the ventromedial hypothalamus) as the
key glucose sensor that coordinates and triggers hypoglycemic counterregulation (8-11).
Insulin receptors are highly expressed throughout the CNS, with specific enrichment in
hypothalamic regions posited to be critical for regulating glucose homeostasis (19-23).
As a result, insulin may play a predominate role in regulating CNS glucose sensing via
glucose

sensing neurons

located

in

the

ventromedial

hypothalamus

(VMH)

(50;57;95;121;122). These glucose sensing neurons share metabolic similarities to other
well-characterized glucose sensing cells (i.e. pancreatic β-cells), especially with regards
to glucose transport and metabolism (44;52;53). Based on the expression of insulin
receptors in the majority of glucosensing neurons in the VMH (68), it is postulated that
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brain insulin action may mediate its effects on central glucose sensing by regulating
expression of glucose transporters (GLUTs) and/or glucokinase (GK). Several members
of the glucose transporter family are expressed throughout the CNS (123). GLUT1 and
GLUT3 are the most abundant isoforms expressed in the brain (63;124-126), whose
functions are thought to maintain basal brain glucose uptake.

GLUT4, the insulin

responsive glucose transporter, is co-expressed with the insulin receptor in several
hypothalamic regions (68) and is down-regulated under diabetic conditions (127).
Subsequent to glucose transport, it may be that the enzyme glucokinase, a key regulator
of glucose phosphorylation and metabolism in the β-cell and liver, may mediate insulin’s
effects on glucose sensing in the hypothalamus (44;55). Similar to insulin receptors,
glucokinase is highly expressed in hypothalamic neurons (44;55;65;66;70;128). Because
insulin signaling regulates glucokinase expression and glucose sensing in liver and βcells (129;130), it is thought that insulin signaling may similarly regulate glucokinase
expression and glucose sensing in the hypothalamus. In this study, the NIRKO mouse
model was utilized to assess insulin’s role in modulating the stress response to low
glucose relative to other stressors. Also, the potential mechanism of CNS insulin action
was examined by evaluating alterations in key glucose sensing proteins that colocalize
with insulin receptors, specifically GLUTs and GK.
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MATERIALS AND METHODS
Animals. Mice homozygous for the floxed insulin receptor allele (IRlox-lox) were bred
with transgenic mice that express Cre recombinase cDNA from the rat nestin promoter to
generate (IRlox-lox:nestin-Cre+/-) nervous system specific insulin receptor knockout
(NIRKO) mice (28). Genotypes were determined by PCR of tail DNA. Unless otherwise
indicated, 2-4 month old NIRKO and littermate control (Control, IRlox-lox:nestin-Cre-/-)
mice were used for these experiments. All mice were housed on a 12-hour light/dark
cycle and fed a standard rodent chow (Mouse Diet 9F, PMI Nutrition International, St.
Louis, MO) ad libitum. All procedures were in accordance with the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health and were approved by
the Animal Studies Committee of Washington University.

Brain Glucose Uptake. Briefly, awake, unrestrained, cannulated NIRKO and littermate
control mice (n=6-9 per group) underwent a 2-hour hyperinsulinemic (40mU/kg/min)
hypoglycemic (30mg/dL) clamp protocol. At 45 minutes prior to the end of the clamp, a
5µCi bolus of

14

C 2-deoxyglucose was rapidly infused intravenously and ten-timed (0,

0.5, 2, 3, 5, 10, 15, 20, 30, and 45 min) arterial blood samples (10µL) were collected for
analysis of arterial plasma glucose and

14

C levels. Immediately after the conclusion of

the clamp, animals were euthanized and brains were rapidly harvested and quickly frozen
in a dry ice and 2-methylbutane (Fisher, Saint Louis, MO) bath (-20o C). Plasma 2-14CDG concentrations were determined by a dual-channel scintillation counter (Tri-Carb
2800TR, PerkinElmer, Waltham, MA). Isotope concentrations in regions of interest,
including the CA1, CA3, and dentate gyrus (DG) of the hippocampus, arcuate nucleus
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(ARC), paraventricular nucleus (PVN), and ventromedial nucleus (VMH) of the
hypothalamus, and nucleus of the solitary tract (NTS), were measured from 20µm thick
coronal serial sections collected on heated coverslips at 60µm intervals. Following,
sections were exposed to autoradiograph film along with precalibrated 14C standards for
2-4 days and analyzed via optical densitometry (ARC 146E, American Radiolabeled
Chemicals, Inc., St. Louis, MO). Regional glucose uptake was calculated according to
Sokoloff’s equation utilizing rat rate constants, as mice rate constants have not been
established (131).

Restraint Stress. Awake, 5-hour fasted, control and NIRKO mice (n=6 per group) were
placed in a mouse restrainer (Braintree Scientific, Braintree, MA) for 45 minutes to
induce restraint stress. Cardiovascular parameters were obtained during the basal period
and during the last 20 minutes of restraint stress using a tail-cuff system (Kent Scientific
Corporation, Torrington, CT).

Blood samples (50µL) were taken by previously

implanted arterial cannula at the beginning and end of the restraint period to measure
plasma epinephrine levels.

Heat Stress. Awake control and NIRKO mice (n=6 per group) were exposed to an
ambient temperature of 42°C for 90 minutes to induce heat stress. Blood samples were
taken at the end of the heat stress period to measure catecholamines (50µL).
Subsequently, cryoprotected brains were analyzed for heat stress induced c-fos
immunostaining, as described in the immunohistochemistry methods section.
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Systemic 2-deoxyglucose induced glucopenia. In awake, 5-hour fasted, control and
NIRKO mice, a single bolus of 2-deoxyglucose (600mg/kg IV, Sigma, St. Louis, MO)
was given to induce glucopenic stress.

Blood samples (100µL) were taken by a

previously implanted arterial cannula at the beginning and end of the stress period to
measure plasma catecholamines and corticosterone levels.

Central 2-deoxyglucose induced glucopenia. Two weeks prior to the study, the animals
were anesthetized with ketamine/xylazine (87 and 13.4mg/kg IP), and microinjection
cannula (Plastics One Inc., Roanoke, VA) were inserted into the third ventricle. For
intracerebroventricular (ICV) injections, a solitary ICV cannula was inserted 1.6mm
posterior to bregma, on the suture line, to a targeted depth of 5.5mm. After a 5-7 day
recovery, mice were anesthetized isofluorane and were implanted with catheters (MRE
025, Braintree Scientific Inc., Braintree, MA) into the femoral artery. The animals were
then allowed approximately 4-7 days to recover prior to the experiment. Simultaneously
during the recovery period, mice were handled daily and the ICV cannula was tested to
minimize stress the day of the experiment.

One the day of the experiment, awake, unrestrained animals were rested 2 hours
following exteriorizing the vessel cannula. A basal blood sample (50µL) was taken at
time 0 to measure basal catecholamine levels. Following, the animals were gently, yet
quickly immobilized to give a single infusion of 2-deoxyglucose (1mg/mouse, Sigma, St.
Louis, MO) or a control artificial cerebrospinal fluid (aCSF) solution and returned to their
home cages.

Blood glucose levels were monitored continuously throughout the
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experiment. At 45 minutes after injection, another blood sample was taken to measure
catecholamine levels.

Animals were sacrificed at 120 minutes and the brains were

cryoprotected for future c-fos analysis. Animals were excluded from analysis if the ICV
cannula was not positioned properly as determined on posthumous examination by track
formation and evidence of Evans blue dye (0.01%).

Immunohistochemistry. Mice anesthetized with isofluorane and transcardially perfused
with 0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA). The brains were immersed in 4% paraformaldehyde
overnight and then cryoprotected in 30% sucrose. Free-floating brain sections (20µm)
were blocked with 30% normal goat serum diluted in 0.1% Triton-100/PBS and then
incubated overnight at 4°C with c-fos antibody (1:2000, Ab-5, Calbiochem, San Diego,
CA) or GLUT4 antibody (1:1000, generously gifted by Dr. M. Mueckler, Washington
University in St. Louis). Subsequently, the sections were mounted on slides and
processed with biotinylated goat anti-rabbit immunoglobulin G (1:200) using the Elite
ABC kit (Vector Laboratories, Burlingame, CA). As a negative control, alternative
sections were incubated without primary antibodies. Regions of interest were identified
using anatomical landmarks to identify the paraventricular nucleus (PVN), arcuate
nucleus (ARC), or ventromedial nucleus (VMH) of the hypothalamus (100). Positively
stained cells were counted by a blinded investigator. Four to six anatomically matched
sections per mouse were quantified for statistical purposes.
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Western Blots. The medial basal hypothalamus, defined anatomically as posterior to the
optic chiasm, anterior to the mammillary body, inferior to the thalamus, and ±1mm lateral
to the midline was dissected and frozen for analysis. Samples were homogenized in
buffer containing 1% Igepal (Sigma, Saint Louis, MO), 0.5% Sodium Dodecyl Sulfate
(SDS) (Sigma, Saint Louis, MO), 0.1 mM Phenylmethylsulfonyl Fluoride (PMSF)
(Sigma, Saint Louis, MO), 1X complete protease inhibitor (Sigma, Saint Louis, MO), 1
mM Sodium Fluoride (NaF) (Sigma, Saint Louis, MO), and 1 mM Sodium
Orthovanadate (Na3VO4) (Sigma, Saint Louis, MO) in phosphate buffered saline
(pH=7.4), centrifuged at 14,000 rpm for 30 minutes, and supernatant was collected.
Homogenized hypothalamic protein extracts (20µg for GLUT1 and GLUT3; 100µg for
GLUT4 and glucokinase) were fractionated by electrophoresis on a 10% Bis-Tris
Criterion XT (Biorad, Hercules, CA) gel and subjected to transfer onto a nitrocellulose
membrane (Biorad, Hercules, CA).

Following, the membranes were immunoblotted

against the following primary antibodies: GLUT1 (1:5000, Chemicon, Temecula, CA),
GLUT3 (1:1000, Chemicon, Temecula, CA), GLUT4 (1:1000, kindly supplied by Dr. M.
Mueckler, Washington University in St. Louis, St. Louis, MO), Glucokinase (1:1000,
Calbiochem, San Diego, CA). The blots were developed using a horseradish peroxidaseconjugated secondary antibody (1:8000, Cell Signaling, Boston, MA). Primary antibody
binding was detected by enhanced chemiluminescence ECL reagents (Perkin Elmer,
Wellesley, MA) on ISO-MAX films and quantified by ImageQuant software analysis
(Amersham Pharmacia, Piscataway, NJ). An antibody against β-actin (1:2000, Sigma,
St. Louis, MO) served as a loading control.
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Immunofluorescence. Mice anesthetized with isofluorane and transcardially perfused
with 0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA). The brains were immersed in 4% paraformaldehyde
overnight and then cryoprotected in 30% sucrose. Briefly, free-floating hypothalamic
sections (20-30µm) throughout the VMH/ARC were taken from 1.46 to 1.82mm caudal
to bregma, blocked, and incubated overnight at 4°C in the GLUT4 primary antibody
(1:1000).

Goat anti-rabbit Texas Red (1:200, Molecular Probes) was used as the

secondary antibody.

Subsequently, the sections were mounted on slides using

Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA). As a negative
control, alternative sections were incubated without primary antibodies.

Regions of

interest were identified using anatomical landmarks (100) and positively stained cells
were counted by a blinded investigator. Four to six brain sections per mouse were
quantified for statistical purposes.

RT-PCR. Sections (400µm) were taken from brain sections 1.46 to 1.86mm caudal to
bregma. 0.5mm bilateral punch biopsies from the VMH and ARC (0.75mm from the
piriform cortex) were collected from NIRKO mice and littermate controls (n=7-8 per
group). The mRNA extracted with Trizol (Invitrogen Corporation, Carlsbad, CA) was
subject to quantitative two-step RT-PCR reaction performed in triplicate in a fluorescent
temperature cycler (GeneAmp 7700 Sequence Detector, Applied Biosystems) with
glucokinase primers (glucokinase probe 5’ -/56-FAM/ACC GCC AAT GTG AGG TCG
GCA /3BHQ_1/-3’; glucokinase reverse 5’- AGC CGG TGC CCA CAA TC- 3’; and
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glucokinase forward 5’- CCA CAA TGA TCT CCT GCT ACT ATG A-3’). The results
were quantified after normalizing to ribosomal RNA L32mRNA.

Statistics. All values are presented as the mean ± standard error of the mean (SEM).
Single comparisons between parameters were tested for statistical significance using a
Student’s t test. For multiple group comparisons, statistical significance was determined
by analysis of variance (ANOVA) using repeated measures followed by a Bonferroni
post-hoc test to assess differences between experimental groups. Statistical significance
was set at p<0.05.
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RESULTS
Absent CNS Insulin Signaling does not Influence Response to Restraint or Heat Stress
It is noted that NIRKO mice have an impaired response to hypoglycemia. Since the
efferent response to stress involves common hypothalamic projections to spinal and
medullary autonomic centers resulting in adrenomedullary activation (132), it was
important to test the adrenomedullary response to other forms of stress in order to
determine whether the impaired stress response in NIRKO mice was unique to
hypoglycemia or part of a more generalized defect in the autonomic nervous system
mediated stress (i.e., fight or flight) response unique to this knockout mouse. NIRKO
and control mice were subjected to two, glycemia-independent, stressors—a mild stressor
(restraint stress) and a more profound stressor (heat stress)—in order to evaluate
sympathoadrenal activation in response to glycemia-independent stress. In response to
milder restraint stress, plasma epinephrine levels were somewhat elevated in the basal
state due to animal handling but rose similarly 2-fold in both littermate controls and
NIRKO mice from this baseline during stress. The physiological increased heart rate to
restraint stress was also similar in control and NIRKO mice (Figure 12). Heat stress
induced a more pronounced catecholamine elevation than restraint stress (to levels within
the range observed during hypoglycemia experiments), but the rise in both epinephrine
and norepinephrine in response to heat stress was again not significantly different
between groups (Figure 13).

To determine whether the impairment in neuronal activation seen in NIRKO mice was
unique to hypoglycemia, c-fos expression was also assessed in response to heat stress.
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Increased c-fos expression was noted in the paraventicular nucleus (PVN) in response to
heat stress (Figure 14), to levels observed with severe hypoglycemia (Figure 8); however,
in response to heat stress, there was no difference in c-fos expression between groups
(Control: 123±4 vs. NIRKO: 129±10, p=NS).

Absent CNS Insulin Action does not Impair Physiological Responses to Systemic nor
Central Cellular Glucopenia
To ascertain whether the impaired counterregulatory response seen in NIRKO mice is
due solely to insulin-induced hypoglycemia, an alternate glucopenic stimulus was
utilized. 2-deoxyglucose (2-DG) is a commonly used agent thought to pharmacologically
simulate hypoglycemia in animals.

2-DG is a non-metabolized glucose analog that

deprives cells of metabolizable glucose, thus inducing a glucoprivic signal that triggers a
counterregulatory response even in the presence of normal systemic glucose
concentrations. Other groups have demonstrated that administration of 2-DG can induce
a profound counterregulatory response in animals, as well as induce neuronal activation
within key glucose sensing regions of the hypothalamus (133;134).

When given

systemically, 2-deoxyglucose increased blood glucose levels in both NIRKO and control
mice (Figure 15). There was also robust stimulation of epinephrine release, similar to
levels induced by insulin-induced hypoglycemia, by NIRKO and control mice. However,
the rise in epinephrine seen in NIRKO mice was not different from that of controls
(Figure 16). Norepinephrine levels were not significantly elevated from baseline levels
in either NIRKO mice or littermate controls in response to 2-DG (Figure 16). Basal
corticosterone levels were lower in NIRKO mice and the incremental response (i.e. delta)
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induced by 2-DG stress was significantly greater in NIRKO mice vs. control mice;
however, peak corticosterone levels during 2-DG stress were comparable to those seen in
control mice (Figure 15).

Subsequent experiments were performed to determine whether the counterregulation
impairment seen in NIRKO mice was centrally-mediated.

2-DG was specifically

administered to the 3rd ventricle of the hypothalamus to cause a localized glucoprivic
insult. In response to central 2-DG, NIRKO and control mice showed a matched rise in
blood glucose (Figure 17).

Norepinephrine was not significantly elevated in either

NIRKO or control mice in response to central 2-DG administration (Figure 17). The
norepinephrine response seen in NIRKO mice was comparable to littermate controls.
Similarly, epinephrine levels trended higher due to 2-DG stress in both control and
NIRKO mice, but the rise was not significant (Control: p=0.09 vs. CSF, NIRKO: p=0.06
vs. CSF) (Figure 17).

Expression of Hypothalamic Glucose Sensors in Model of Abrogated Insulin Action
To assess whether CNS insulin action regulates key glucose sensors, including
glucokinase (GK) and glucose transporters (GLUTs), in the brain, hypothalamic protein
and mRNA expression was assessed. GK protein levels in the hypothalamus were
comparable in control and NIRKO mice (Figure 18).

GK mRNA expression was

preferentially expressed in the VMH and arcuate nucleus, but there was no difference in
expression levels between experimental groups (Figure 18), consistent with the
glucokinase protein expression findings. Hypothalamic protein expression of GLUT1
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and GLUT3 were 3-fold higher than hypothalamic protein expression of GLUT4.
Relative to controls, GLUT1 protein levels in the hypothalamus were similar in NIRKO
mice (Figure 19). Hypothalamic GLUT3 protein levels in NIRKO mice were slightly
(80.5±9.8% of control), but not significantly (p=0.08) reduced (Figure 19). Interestingly,
insulin-regulated GLUT4 protein levels were significantly reduced (68.5±5.5% of
control, p<0.05) in the hypothalamus of NIRKO mice (Figure 19). When assessing
GLUT4 regional localization, immunohistochemistry results demonstrated that GLUT4
protein was highly enriched in the ventromedial hypothalamus (VMH) and the arcuate
nucleus (ARC) of control mice.

In NIRKO mice, GLUT4 protein expression was

markedly reduced in these regions (Figure 20).

Regional Brain Glucose Uptake during Hypoglycemia is not Altered in NIRKO Mice
Based on the impaired glucose sensing and reduced GLUT4 expression found in NIRKO
mice, it was postulated that glucose uptake might be altered in critical glucose sensing
areas of NIRKO mice. To measure regional specific brain glucose uptake, radiolabeled
14

C-2-deoxyglucose infusions during hyperinsulinemic-hypoglycemic clamps were used.

In spite of reductions in glucose transporter expression in NIRKO mice, regional brain
glucose uptake was not different between experimental groups within any areas assessed
(Figure 21).
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Figure 12. NIRKO mice have a normal physiological response to restraint stress.
NIRKO (n=6, closed bars) and littermate control (n=6, open bars) mice were placed into
a confining restraint device for 45 minutes. A&B. Plasma epinephrine levels (A) and
heart rates (B) were elevated in response to restraint stress, but equally in control and
NIRKO mice. (*p<0.05 vs. basal)

43

Epinephrine (pg/mL)

3000
2500
2000
1500
1000
500
0

Norepinephrine (pg/mL)

Control NIRKO
6000
5000
4000
3000
2000
1000
0

Control NIRKO

Figure 13. NIRKO mice display normal catecholamine responses to heat stress.
NIRKO (n=6, closed bars) and littermate controls (n=6, open bars) were subjected to heat
stress for 90 minutes. Plasma epinephrine (top) and norepinephrine (bottom) levels were
significantly stimulated by heat stress; however, there was no difference between NIRKO
and control mice.
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Figure 14. Normal neuronal activity in response to heat stress seen in NIRKO mice.
NIRKO (n=6, closed bars) and littermate controls (n=6, open bars) were subjected to heat
stress for 90 minutes. Top: Representative images of matched hypothalamic sections
highlighting heat stress induced c-fos staining in the paraventricular nucleus (PVN).
Bottom: Graph quantifying c-fos positive cells shows no difference between NIRKO
and controls.
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Figure 15. NIRKO mice show normal physiological response to systemic glucopenic
stress. Top: Blood glucose levels were similarly elevated in NIRKO (closed circles)
and control (open circles) mice following 2-DG administration (as indicated by arrow).
Bottom: In NIRKO (closed bars) mice, basal corticosterone levels were slightly lower
than controls (open bars). As a result, the rise (i.e. delta) in corticosterone seen in
NIRKO mice is significant; however, relative to controls, 2-DG stress induced
corticosterone levels were not different between NIRKO and littermate control mice.
(*p<0.05 vs. control)
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Figure 16. Catecholamine response to systemic glucopenic stress. Top: Epinephrine
levels were significantly elevated in both NIRKO mice and littermate controls. Bottom:
Norepinephrine levels were slightly, but equally elevated by 2-DG stress in both NIRKO
and control mice. (*p<0.05 vs. control)
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NIRKO mice.

NIRKO

Central glucopenic stress induces modest physiological response in
Top: Basal and peak blood glucose profile from NIRKO and

control mice after 2-DG (closed bars) or aCSF (open bars) administration (n=4-7 mice
per group). Center: Norepinephrine levels were similarly induced by 2-DG stress in
NIRKO and littermate controls. Bottom: Epinephrine levels trended higher in response
to 2-DG; however, these responses were comparable between groups. (*p<0.05 vs. CSF)
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Figure 18. Glucokinase expression is not altered in NIRKO brains. Top: Western
blots of whole hypothalamic extracts from NIRKO and littermate controls (n=5-6 mice
per group). Graph quantifying protein expression (representative images below) is shown.
Bottom: Although glucokinase mRNA was highly expressed in the ventromedial
hypothalamus (VMH) and arcuate nucleus (ARC) as compared to the cortex, there was
no difference between NIRKO (n=7, closed bars) and controls (n=8, open bars).
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GLUT3
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Insulin-regulated glucose transporter 4, not GLUT1 or GLUT3, is

reduced in NIRKO brains. Western blots of whole hypothalamic extracts from NIRKO
and littermate controls (n=5-6 mice per group) were performed. Representative images
(top) and graph (bottom) quantifying protein expression of glucose transporters (GLUT1,
GLUT3, and GLUT4) are shown. (**p<0.01 vs. control)
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Figure 20. GLUT4 expression is specifically reduced in key glucose sensing regions
of the hypothalamus in NIRKO mice. Regional localization of GLUT4 protein content,
as determined by hypothalamic DAB staining (left) and immunofluorescence (right) of
control (above) and NIRKO (below) mice, show enriched GLUT4 protein content in the
ventromedial hypothalamus (VMH, circled) and arcuate nucleus (triangle) of control
mice. GLUT4 protein content was 62±6% lower in NIRKO mice.
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Figure 21. Glucose uptake during hypoglycemia is preserved in the NIRKO brain.
Regional brain glucose uptake was quantified using

14

C 2-deoxyglucose during a

hyperinsulinemic hypoglycemic (~30mg/dL) clamp. Results show that regional brain
glucose uptake in all regions measured [hippocampus (CA1, CA3, DG), hypothalamus
(VMH, ARC, PVN), and hindbrain (NTS)] are similar among NIRKO (n=6, closed bars)
and control mice (n=9, open bars).
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DISCUSSION
In this study, it was determined that lack of insulin receptor signaling in the central
nervous system does not restrict the sympathoadrenal response to various glycemiaindependent stressors, but specifically alters glucose sensing in response to insulininduced hypoglycemia and alters the expression of a key glucose sensor, GLUT4, in the
brain. These findings indicate that insulin acts in the brain to uniquely regulate CNS
glucose sensing and the sympathoadrenal response to hypoglycemia.

Since the adrenomedullary response to hypoglycemia was not impaired during mild
hypoglycemia in NIRKO mice, it was speculated that mild (restraint) stress, as noted by
modest elevations in epinephrine levels (Figure 12), might not have been of sufficient
magnitude to detect a differential response between control and NIRKO mice. However,
by achieving comparable epinephrine levels during severe stress (heat) and severe
hypoglycemia (30mg/dL) and finding a normal catecholamine response to heat stress in
NIRKO mice, these findings indicate that absent CNS insulin signaling does not impair
the normal adrenomedullary response even to severe non-hypoglycemic stress (Figures 9
and 13).

Further, in response to a non-hypoglycemic stressor, heat stress increased c-fos
expression to a similar magnitude as observed during severe hypoglycemia (30mg/dL);
however, no difference in heat-induced c-fos expression was noted between control and
NIRKO mice (Figure 14).

These results indicate that NIRKO mice have an intact

neuronal circuitry for sensing and responding to non-hypoglycemic stress; therefore, the
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impaired responses to hypoglycemia in the NIRKO mice appear to be unique to
hypoglycemic stress and/or glucose sensing.

2-deoxyglucose (2-DG) is a commonly used agent as it is thought to serve as an insulinindependent, pharmacologically-induced hypoglycemia mimetic. Similar to glucose, 2DG is transported into cells via facilitative glucose transporters and phosphorylated via
hexokinases. However, because 2-DG lacks a hydroxyl group, it is not recognized by
fructose isomerase and cannot be converted to fructose-6-phosphate, thus inhibiting its
ability to undergo further glycolysis. Furthermore, 2-DG effectively titrates away key
glycolytic machinery, especially hexokinases, needed for normal glucose metabolism, in
effect, ceasing glycolysis and causing a cellular starvation signal even in the presence of
glucose abundance.

Because 2-DG causes a cell to sense low glucose, it has been considered analogous to
hypoglycemia for many experimental designs. Unfortunately, the inability to accurately
equate a dose of 2-DG to a corresponding degree of hypoglycemia precludes our ability
to directly compare these two stressors. In several studies, 2-DG has been used as a
hypoglycemia surrogate in rat and mouse models of impaired counterregulation
(58;75;135-139). Data from these model systems predominately observed impairments
of the counterregulatory glucagon response. Of note, several studies (particularly mouse
studies) failed to report if defects extended to other components of glucose
counterregulation, namely catecholamine responses (58;75;137). In this study, we found
2-DG to stimulate the adrenomedullary response in NIRKO mice similarly to controls,
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whether given systemically or centrally (Figures 16 and 17).

As we observed a

prominent adrenomedullary impairment resulting from insulin-induced hypoglycemia in
the NIRKO model, these results suggest that 2-DG is not an equivalent stressor as
insulin-induced hypoglycemia in our model. It is possible, due to the nature of the agent,
2-DG may have directly activated downstream glucose sensors to normalize the
counterregulatory response in NIRKO mice. For example, the activity of nutrient sensor,
AMPK, is increased by 30-50% in key hypothalamic regions of rats treated with 2-DG
(137). Since AMPK is an important modulator of hypoglycemic counterregulation and
its activity is associated with augmented counterregulatory responses (81;83;137;140), it
is plausible to speculate that 2-DG restored the counterregulatory defect in NIRKO mice
by targeting AMPK or other downstream glucose sensors. However, additional studies
are required to address the specific mechanism of action.

Similar to its well-characterized actions in muscle and fat, insulin-mediated GLUT4
translocation has been demonstrated in neuronal cell lines (141), hippocampus (142), and
hypothalamus (143). This translocation to the plasma membrane is decreased in the
brains of insulin resistant rats (142;143). GLUT4 mediated glucose sensing has been
speculated to be important at low glucose concentrations, where insulin-mediated glucose
transport may act to supplement low intracellular glucose levels in hypothalamic glucose
sensing neurons (57;122). Indeed, supporting a glucosensing role for insulin receptors
and GLUT4 is their coexpression in up to 75% of glucose responsive neurons in the
VMH (68). Further, neuronal GLUT4 has recently been shown to be an important
mediator of hypoglycemic counterregulation and glucose sensing, as noted in neuronal

55

GLUT4 knockout mice (144). During hypoglycemia, when glucose transport becomes
rate-limiting (145), it was speculated that decreased GLUT4 expression and/or deficient
insulin action would result in reduced glucose uptake in critical glucose sensing regions
of NIRKO mice. This study, however, noted equal regional brain glucose uptake during
the hyperinsulinemic-hypoglycemic clamp (Figure 21), indicating that neither deficient
insulin signaling nor the reduced GLUT4 levels altered glucose uptake in these brain
areas. Since brain GLUT4 expression is much lower than other glucose transporters, it is
likely that glucose uptake was primarily regulated by the (insulin-independent and) more
abundant GLUT1 and GLUT3, thus masking any subtle effect caused by decreased
GLUT4. While regional brain glucose uptake was not altered in NIRKO mice, an effect
of insulin signaling and/or GLUT4 availability on mediating glucose uptake in individual
glucose sensing neurons cannot be ruled out.

The enzyme glucokinase (GK) has also been implicated as a mediator of CNS glucose
sensing. GK expression has been demonstrated in hypothalamic neurons by in-situ
hybridization and RT-PCR (70).

Further, studies have shown that modulation of

hypothalamic GK activity can alter the counterregulatory response to hypoglycemia
(55;71). Since insulin signaling regulates GK expression and glucose sensing in liver and
β-cells (129;130;146), we postulated that insulin may also regulate GK expression in the
brain. Similar to the β-cell (βIRKO) (129) and liver (LIRKO) (146) specific insulin
receptor knockout models, we expected impaired hypoglycemic counterregulation and
glucose sensing to correlate with decreased GK expression in NIRKO mice. Our studies,
however, found no changes in GK expression (Figure 18). Although we cannot rule out
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an effect of insulin on GK activity, based on normal hypothalamic mRNA and protein
expression in NIRKO mice, insulin’s effect on glucose sensing likely lies downstream of
the glucose phosphorylation step.

In the absence of a change in hypothalamic glucose uptake or glucokinase expression, it
may be that insulin acts on glucose sensing hypothalamic neurons (or glia) via
downstream metabolic effectors that limit net glycogen breakdown (147), inhibit AMPK
(82), increase glycolysis and change NADH levels (50;51), modify ATP/ADP ratio
(52;121;148;149), or insulin may directly regulate ATP-activated Cl- channel
(101;119;150) or KATP channel activity (121;151;152) through actions of 3’phospholipids (153;154).

In summary, it is shown that the chronic lack of insulin receptor signaling in the central
nervous system decreases hypothalamic glucose transporter 4 expression, which may
mediate insulin’s effects on CNS glucose sensing.

Further, the impaired

sympathoadrenal response observed in NIRKO mice appears to be specific for glucose
sensing, as the lack of CNS insulin signaling does not restrict neuronal activation or the
adrenomedullary response to other generalized stressors. It is concluded that insulin acts
directly in the brain to uniquely regulate CNS glucose sensing via GLUT4.

By

identifying GLUT4 as a key mediator of CNS insulin action, we are closer to uncovering
the full mechanism by which insulin regulates central nervous system glucose sensing.
This knowledge will allow us to identify key therapeutic targets to improve consequences
associated with insulin-induced hypoglycemia in patients with diabetes.
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THESIS DISCUSSION
Hypoglycemia continues to be a barrier in achieving glycemia control for patients with
Type 1 and advanced Type 2 diabetes.
appropriate

sympathoadrenal

Impaired brain glucose sensing limits the

counterregulatory

response

and

contributes

to

hypoglycemia unawareness, thus increasing the frequency and severity of hypoglycemia
for patients with diabetes.

Unraveling the biology of neuronal glucosensing, the

experiments in this thesis demonstrated a key role of CNS insulin signaling in regulating
hypoglycemic counterregulation and glucose sensing. Further, we have highlighted the
role of a key component mediating insulin’s central effects, GLUT4, which can serve as a
likely therapeutic target for preventing hypoglycemia caused by intensive insulin therapy.

Insulin Therapy
Glycemic control is the primary goal of diabetes therapy. Unfortunately, achieving nearnormal glucose levels is often complicated by high variability with traditional insulin
treatments.

Determining appropriate doses, timing, and routes of insulin delivery,

conventional glucose management poses an enormous challenge in achieving and
maintaining stable glucose levels. In light of evidence of insulin’s role in the brain to
regulate glucose homeostasis, prescribing the right insulin therapy now adds an additional
level of complexity to glycemic management. With the development of novel insulin
analogues (Glargine (Lantus), Detemir (Levemir), intra-nasal insulin, inhaled insulin,
etc.), patients with diabetes are able to improve glycemic control while limiting
additional risks associated with intensive therapy.

However, these analogues have

different pharmacodynamic properties that could enhance or restrict insulin transport
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across the blood-brain-barrier (BBB) and thus alter the extent of insulin action in the
CNS. Normally, circulating insulin crosses the BBB via a saturable transport mechanism
(35). Yet, certain insulin analogues can cross the BBB more easily than human insulin,
thus enabling it to enhance insulin signaling in targeted brain regions and modulate the
counterregulatory response to hypoglycemia.

For example, the long-acting acylated

insulin analogue Determir may enhance CNS insulin signaling. Due to the lipophilic
nature of Detemir, it may more easily cross the BBB relative to human insulin. In mice,
detemir administration resulted in higher hypothalamic insulin signaling compared to
human insulin (155). Further, detemir treatment is associated with lower incidences of
hypoglycemia, less weight gain, and higher degrees of symptom awareness during
hypoglycemia (156;157), indicative of enhanced CNS insulin signaling. Similarly, intranasal insulin can bypass the BBB, directly targeting brain tissue (158;159). Although it is
a less common treatment, intra-nasal administration is associated with reduced bouts of
hypoglycemia (160;161).

Given the importance of aggressive insulin therapy in

achieving and maintaining intensive blood glucose control, the extent to which insulin
analogues act in the CNS is an important factor to consider as patients and healthcare
providers assess the role of insulin action in the brain in mediating glucose sensing and/or
the counterregulatory response to hypoglycemia.

CNS Insulin Action
Insulin and insulin signaling have been widely studied in classic “insulin-sensitive”
peripheral tissues (i.e. fat, muscle, liver) for decades; yet, only recently has insulin action
garnered appreciation for its role in the brain. Centrally, insulin signaling influences
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divergent metabolic pathways. Of particular interest, brain insulin action has a novel role
in regulating glucose homeostasis. Unlike its peripheral actions to suppress hepatic
glucose outflow, CNS insulin action enhances glucose output under conditions of
hypoglycemia. This dichotomous role of insulin action protects the body against overt
glucose fluctuations and the associated consequences of glycemic dysregulation. In this
study, we examined the role of CNS insulin action in regulating the counterregulatory
response to hypoglycemia. The CNS-specific insulin receptor knockout (NIRKO) mouse
was a powerful model system to conduct these experiments as it allowed us to isolate and
clarify insulin’s role in a targeted tissue. This study informed us of insulin’s unique role
in regulating the adrenomedullary response to hypoglycemia. It also highlighted its
involvement in CNS glucose sensing. Further, it gave us clues as to the specific site(s)
and mechanism of CNS insulin action.

In particular, this study recognized the ventromedial hypothalamus (VMH) as a potential
site of CNS insulin action. Elegant studies performed by Borg and colleagues, among
others, illustrated the role of the VMH in CNS glucose sensing and glucose homeostasis
(11;48-50). With its targeted enrichment of insulin receptors and high population of
glucosensing neurons, the VMH was postulated to be the most likely site of CNS insulin
action. These studies revealed key impairments of glucose sensing in VMH neurons and
a distinct reduction in the key glucose sensing protein GLUT4 of NIRKO mice. Overall,
these results suggest the VMH serves as a site of insulin action; however, modifications
observed in other brain regions suggest that the VMH is not the sole site of CNS insulin
action.
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The paraventricular nucleus (PVN) of the hypothalamus may also be a key site of insulin
action. In this study, impaired c-fos activity was predominately observed in this region.
The PVN is primarily thought of as an integrating center of neuronal inputs. Receiving
input signals from the VMH and sending projections to autonomic centers, the PVN main
purpose may be to serve as a second-level hypoglycemic detector that propagates
neuronal responses initiated within the VMH. However, the PVN also contains a large
subset of glucose sensing neurons and a demonstrated role in hypoglycemic
counterregulation (114;162). As a consequence, the PVN may also act as a distinct,
primary site of hypoglycemic detection and a key site of CNS insulin action. The panneural insulin receptor knockout of the NIRKO model established the importance of
insulin action in the brain; however, additional studies are needed to clearly and
definitively isolate specific nuclei as primary site(s) of insulin action. Some studies have
created hypothalamic specific insulin receptor knockdown models (95;143;163) to
pinpoint the CNS site of insulin action. Similar to NIRKO mice, targeted reductions in
hypothalamic insulin receptor expression resulted in hyperphagia, weight gain, and
insulin resistance in rats (95;143;163). These studies also noted a reduction of plasma
membrane GLUT4 expression in the hypothalamus (143).

Nevertheless, additional

studies are required to unequivocally locate the specific site of CNS insulin action.
Taking advantage of these approaches or generating nuclei- or cell type-specific insulin
receptor knockout models via other transgenic, viral, or pharmacological approaches, the
primary site(s) of CNS insulin action in regulating glucose sensing and the hypoglycemic
counterregulatory response can be determined.
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Insulin and Glucose Sensing Neurons
Although the focal point of CNS insulin signaling is yet to be defined, this report
demonstrates a significant role of insulin in influencing a specialized neuronal population
of glucose sensing neurons (GSN).

Stimulated by fluxes in ambient glucose

concentrations, it is believed that GSNs evolved to protect the brain against
pathophysiologic glucose fluctuations, especially bouts of hypoglycemia (164). As a
result, GSNs are considered the primary modulators of glucose sensing and glucose
counterregulation in the brain. This thesis demonstrated impaired glucose responsiveness
of hypothalamic glucose-inhibited (GI) neurons in NIRKO mice.

As the primary

function of GI neurons is believed to stimulate hypoglycemic counterregulation, this
glucose sensing impairment correlated well with the impaired sympathoadrenal response
to hypoglycemia noted in the NIRKO model. Similar to GI neurons, in vitro studies have
also indicated a role for insulin to act directly on the glucose-excited (GE) neurons as
well. Previous studies have shown insulin to increase action potential frequency of
arcuate nucleus glucose-excited neurons under conditions of low glucose (42). Other
studies have shown insulin to hyperpolarize VMH glucose-excited neurons by opening
ATP-sensitive K+ channels (72;121). Although GE neurons are presumably quiescent
during hypoglycemia, these studies suggest that insulin may also regulate the glucose
responsiveness of GE neurons, subsequently to regulate the counterregulatory response to
hypoglycemia.

It is unclear which aspects of glucose counterregulation are affected by the different
subsets of GSNs or if they play distinct roles in regulating the counterregulatory
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response. However, emerging evidence suggest that GSNs may have distinct functions to
coordinate the full counterregulatory response to hypoglycemia. Some studies attribute
the sympathoadrenal response to GI neurons while the glucagon response to
hypoglycemia may be primarily regulated by GE neurons (102;165;166). Due to the
discrete localization of glucose sensing neurons in the VMH and technical challenges
involving in isolating glucose sensing neurons, glucose responsiveness of GE neurons
were not analyzed in our NIRKO mice. Since insulin can influence both GI and GE
neurons, it is fair to speculate that, similar to GI neurons, some, if not all, parameters of
glucose responsiveness would be impaired in NIRKO GE neurons. Alternatively, due to
the intact glucagon response evident in the NIRKO model, glucose sensing in GE
neurons may be preserved. In either case, evaluating glucose sensing in NIRKO GE
neurons would further highlight the importance of CNS insulin action in central glucose
sensing. It could also uncover the interplay between the two types of glucose sensing
neurons and how they might communicate to regulate glucose sensing and hypoglycemic
counterregulation.

CNS Insulin Action and Downstream Glucose Sensors
Insulin receptor signaling is an elaborate signaling cascade that coordinates the
activation/regulation of a number of downstream mediators to facilitate insulin’s effects
on various metabolic processes.

In peripheral glucose sensing, the mechanism of

insulin’s actions on various sensing proteins are well-defined. Whether central insulin
signaling mimics peripheral action is unclear; however, identification of shared and novel
CNS insulin action mediators draws us closer to defining the mechanism of CNS insulin
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action. One major mediator of peripheral insulin action is the family of facilitative
glucose transporters (GLUTs). Predominately, GLUT4 is a primary target of peripheral
insulin action. This insulin-regulated transporter plays a key role in maintaining glucose
homeostasis by enhancing insulin stimulated glucose uptake in peripheral tissues.

Due

to colocalization with insulin receptor in key glucosensing areas, it was speculated that,
similar to peripheral actions, insulin may regulate brain GLUT4 (68), such that impaired
GLUT4 activity and/or expression might contribute to defective CNS glucose sensing
observed in the NIRKO mouse. Previous studies have shown that GLUT4 is localized to
glucosensing regions of the hypothalamus and GLUT4 expression is down-regulated
under diabetic conditions (127;142).

In this thesis, immunohistochemistry results

indicated that GLUT4 protein expression was markedly decreased (to approximately 30%
of controls) in the ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) of
NIRKO mice. These results suggest that insulin acts in the brain to regulate glucose
transporter expression in critical glucose sensing regions of the hypothalamus.
Corroborating an important role of brain GLUT4, neuronal specific GLUT4 knockout
mice also demonstrate impaired glucose sensing and hypoglycemic counterregulation
(144).

Glucokinase (GK) has also been shown to be important sensing protein in glucosensing
neurons (55;68;75;167) and may also mediate insulin’s effects within the brain. In this
study, there were no changes in GK expression levels; however, activity was not assessed
in this study.

Due to glucokinase’s demonstrated role in regulating hypoglycemic

counterregulation, it is worthwhile to assess insulin’s direct effects on GK activity. Other

64

potential glucose sensors that may mediate insulin’s central effects are ATP-sensitive ion
channels and the fuel gauge AMPK. Similar to GLUTs and GK, mounting evidence
highlights the emerging roles of both ion channels and AMPK in mediating hypothalamic
glucose sensing (74-76;81-83;168). Spanswick and others found that insulin can regulate
GE neuronal responsiveness via KATP activation (121;122). In the periphery, the effects
on insulin on AMPK activity have been variable. In the heart, insulin inhibits AMPK
(169;170) while reduced insulin signaling correlated to decreased AMPK activity in
trophoblast stem cells (171). There is also some evidence that insulin may regulate
hypothalamic AMPK activity (82); however, the nature of insulin’s effects on
hypothalamic AMPK activity must be further clarified. By evaluating insulin’s effects on
these downstream glucose sensors in further detail, a clear description of insulin’s
mechanism of CNS action will develop.

Summary
On a quest to achieve near-normoglycemia, hypoglycemia and impaired glucoregulation
are serious challenges faced by insulin-treated diabetic patients. Insulin effects extend
beyond classic insulin-sensitive tissues to include major influences in the brain to
regulate glucose homeostasis, central nervous system (CNS) glucose sensing, and the
counterregulatory response to hypoglycemia. The experiments in this thesis investigated
insulin’s role in regulating hypothalamic glucose sensing and the counterregulatory
response to hypoglycemia. Utilizing a genetic mouse model which chronically lacks
CNS insulin action (NIRKO mouse), this report demonstrated CNS insulin action to
regulate the glucose sensitivity of glucose sensing neurons in the VMH. This report also
showed CNS insulin action to uniquely modulate hypothalamic neuronal activation and
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the sympathoadrenal response to hypoglycemic stress, not other stressors. Finally, it was
found that insulin action in the brain regulates GLUT4 expression, which may operate as
the primary mediator of CNS insulin action. Results of this study provided novel insights
into insulin’s role in regulating CNS glucose sensing and the counterregulatory response
to hypoglycemia. This insight can aid in the overall understanding as to how the brain
regulates the counterregulatory response to hypoglycemia in order to devise therapies to
combat severe hypoglycemia.
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